Advanced Enzyme Q1 FY27: Profit down, ₹69.7cr buyback

Results announced after August 8 board meeting

Advanced Enzyme Technologies announced its first-quarter FY2026-27 results on Saturday, August 8. Alongside the financials, the board approved a share buyback through the open market route and a set of corporate actions involving subsidiaries. The quarter under review ended June 30, 2026, and the company said the unaudited results were reviewed by the statutory auditors. The auditors expressed an unmodified conclusion in the limited review report, as disclosed with the results.

The updates matter for investors because they combine near-term operating trends with capital allocation decisions. The quarter showed pressure on profitability metrics compared with the year-ago period, while revenue was broadly stable on a consolidated basis. The board decisions also included a move to consolidate ownership in an existing subsidiary.

Consolidated performance: revenue up, profit lower

On a consolidated basis, revenue from operations stood at ₹189.79 crore for the quarter ended June 30, 2026. This compared with ₹185.91 crore in the corresponding quarter last year, as per the company’s disclosed figures. Other income was ₹13.02 crore, taking total income to ₹202.81 crore.

Net profit for the quarter on a consolidated basis was ₹38.59 crore, compared with ₹40.44 crore in the corresponding quarter of the previous year. The company also disclosed that net profit attributable to shareholders stood at ₹37.09 crore for the quarter ended June 30, 2026, compared with ₹39.93 crore in the corresponding quarter last year. Profit before tax was ₹53.53 crore versus ₹54.90 crore in the year-ago quarter.

Separately, the company’s topline was also described as rising 2.2% to ₹190 crore from ₹186 crore, while net profit was stated at ₹37 crore versus ₹40 crore. These figures align broadly with the consolidated results and the attributable profit disclosed in the financial highlights.

EBITDA and margins: year-on-year pressure

The company reported that EBITDA slipped 9.6% year-on-year. EBITDA declined to ₹51.10 crore from ₹56.50 crore, based on the figures provided. Operating margin also weakened, with EBITDA margin falling to 26.9% compared with 30.38% year-on-year.

These profitability movements suggest that costs rose faster than operating income in the period, even as revenue held up. The disclosed consolidated expenses for the quarter were ₹149.28 crore, compared with ₹139.86 crore in the year-ago quarter. The company did not attribute the changes to any single factor in the information provided, but the margin movement is clearly reflected in the reported numbers.

Standalone snapshot: lower revenue, profit around ₹22.35 crore

On a standalone basis, revenue from operations was ₹115.86 crore for the quarter ended June 30, 2026, compared with ₹125.02 crore in the corresponding quarter of the previous year. Standalone net profit was ₹22.35 crore for the same quarter, compared with ₹73.98 crore in the year-ago quarter, as per the table shared.

The standalone table also showed profit before tax at ₹29.74 crore in Q1 FY27, compared with ₹81.40 crore in Q1 FY26. The large year-on-year shift in standalone profit stands out in the disclosed data and is distinct from the smaller change seen at the consolidated level.

Buyback approved: size, price, route, and eligibility

The board approved a buyback of fully paid-up equity shares with a face value of ₹2 each. The maximum buyback price is ₹500 per share, with an aggregate buyback size not exceeding ₹69.70 crore. The company said the buyback will be executed via the stock exchange mechanism through the “Open Market” route.

As disclosed, the buyback will be conducted from shareholders other than promoters, the promoter group, and persons in control of the company. At the maximum buyback size and maximum buyback price, the indicative maximum number of shares to be bought back is 13,94,000 equity shares. This represents 1.24% of the existing paid-up equity capital, based on the company’s statement.

Subsidiary actions: JC Biotech and Nutrazyme

The board also approved the acquisition of the remaining 4.28% stake in JC Biotech Private Limited (JCB) from the existing shareholders. The total consideration disclosed for this acquisition is ₹7.98 crore. JCB was described as an existing subsidiary with 95.72% holding prior to the transaction, and the company said it will become a wholly owned subsidiary upon completion.

In addition, the board approved an additional fund infusion of up to ₹2.00 crore in Advanced Nutrazyme Private Limited. The company also disclosed that Advanced Nutrazyme’s revenue in FY 2026 was ₹0.002 crore.

Key numbers table: consolidated financials

All figures below are converted to ₹ crore from the company’s ₹ million disclosure.

Stock reaction and recent price performance

Shares of Advanced Enzyme Technologies closed lower by 1.79%, down ₹5.90, based on the information provided. The stock price referenced was ₹323.90 per share. Over the past six months, the shares have risen 11.08%, as stated.

The company’s market activity also included a trading window closure until August 10, 2026, cited as part of compliance ahead of the results. Separately, the company had announced July 24, 2026 as the record date to determine shareholder eligibility for a final dividend of ₹1.35 per share for FY 2025-26.

Why the update matters for investors

The quarter combines mixed operating signals: relatively steady consolidated revenue alongside lower profitability and a weaker EBITDA margin. At the same time, the board’s approval of a buyback up to ₹69.70 crore sets a defined framework for potential cash deployment in the market, with a stated cap price of ₹500.

The move to acquire the remaining stake in JC Biotech and make it wholly owned is a separate capital allocation decision, with a disclosed consideration of ₹7.98 crore. The additional infusion planned for Advanced Nutrazyme, up to ₹2.00 crore, indicates further funding support for a group entity that reported very small revenue in FY 2026.

Conclusion

Advanced Enzyme’s Q1 FY27 disclosures show softer profitability, with consolidated net profit at ₹38.59 crore and EBITDA at ₹51.10 crore alongside a lower margin of 26.9%. The board simultaneously approved an open-market buyback up to ₹69.70 crore and cleared steps to take JC Biotech to 100% ownership. The next key milestones for shareholders will be the company’s execution details under the SEBI buyback framework and completion of the JC Biotech stake acquisition, as outlined in the board decisions dated August 8, 2026.